[The influence of lamivudine therapy on the course of chronic hepatitis B in renal allograft recipients].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Wpływ leczenia lamiwudyna na przebieg przewlekłego wirusowego zapalenia watroby typu B u biorców nerki allogenicznej.
    • Source:
      Publisher: Aluna Publishing Country of Publication: Poland NLM ID: 9705469 Publication Model: Print Cited Medium: Print ISSN: 1426-9686 (Print) Linking ISSN: 14269686 NLM ISO Abbreviation: Pol Merkur Lekarski Subsets: MEDLINE
    • Publication Information:
      Publication: 2023- : Konstancin-Jeziorna, Poland : Aluna Publishing
      Original Publication: Warszawa : MEDPRESS, [1996-
    • Subject Terms:
      Kidney Transplantation*; Hepatitis B, Chronic/*drug therapy ; Lamivudine/*pharmacology ; Lamivudine/*therapeutic use ; Reverse Transcriptase Inhibitors/*pharmacology ; Reverse Transcriptase Inhibitors/*therapeutic use; Adult ; Alanine Transaminase/metabolism ; Female ; Humans ; Lamivudine/adverse effects ; Male ; Middle Aged ; Recurrence ; Reverse Transcriptase Inhibitors/adverse effects
    • Abstract:
      The aim of this study was to evaluate efficacy and safety of lamivudine therapy in renal allograft recipients with chronic hepatitis B infection. Twenty-four patients with chronic hepatitis B after renal transplantation were observed. We obtained HBV replication blockage in 95% of patients, in half of them also ALT normalisation was observed. Delayed HBV replication blockage was observed in patients with prolonged duration of haemodialysotherapy or HBV infection and HCV coinfection, although listed parameters did not influence overall treatment efficacy. After lamivudine discontinuation HBV replication relapsed, in part of patients with ALT activity elevation. We did not observed any serious adverse reactions under lamivudine therapy.
    • Accession Number:
      0 (Reverse Transcriptase Inhibitors)
      2T8Q726O95 (Lamivudine)
      EC 2.6.1.2 (Alanine Transaminase)
    • Publication Date:
      Date Created: 20040221 Date Completed: 20040506 Latest Revision: 20131121
    • Publication Date:
      20221213
    • Accession Number:
      14974368